Dapagliflozin: BMS 512148; BMS-512148.
Dapagliflozin, a selective inhibitor of the sodium glucose co-transporter type 2 (SGLT2) is in development for type 2 diabetes mellitus with Bristol-Myers Squibb and AstraZeneca. It is currently undergoing phase III development worldwide with regulatory submissions expected in the second half of 2010. This review looks at the development history and scientific profile of this drug to date.
D000818:Animals; D001559:Benzhydryl Compounds; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D005960:Glucosides / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000077203:Sodium-Glucose Transporter 2 Inhibitors
D001559:Benzhydryl Compounds; D015507:Drugs, Investigational; D005960:Glucosides; D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C529054:dapagliflozin